The authors regret mentioning potential misinformation for few products in Tables
2 and 3 of the above article (Volume 39, Number 7, pp. 782–786). The complete details and updates are summarized below:
|
Page No.
|
Column head
|
Row
|
Potential misinformation
|
Corrected information
|
|
Table 2
|
|
783
|
Potential risks
|
Kogenate FS (Bayer)
|
Allergic type hypersensitivity reactions; risk of infection from unknown/emerging
viral/other pathogens; risk of thrombotic events; formation of neutralizing antibodies;
thrombophlebitis/thrombosis at infusion/catheter site
|
Allergic type hypersensitivity reactions; risk of thrombotic events; formation of
neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site
|
|
784
|
Potential risks
|
Xyntha/ReFacto AF (Pfizer)
|
Allergic type hypersensitivity reactions; risk of infection from unknown/emerging
viral/other pathogens; formation of neutralizing antibodies; lack of effect (bleeding
events)
|
Allergic type hypersensitivity reactions; formation of neutralizing antibodies; lack
of effect (bleeding events)
|
|
Table 3
|
|
786
|
Purification
|
BeneFIX (Pfizer)
|
Immunoaffinity chromatography
|
Affinity chromatography
|
